This is one of the most common questions about GLP-1 drugs, and the short answer is yes and no. The molecule is the same; the products aren't. FDA approved them separately, four years apart, for different conditions [4] [5]. The semaglutide guide covers the molecule itself; this page covers what separates the two boxes.
Same molecule, same maker
Both are weekly injections of semaglutide from Novo Nordisk. Semaglutide acts on the GLP-1 receptor, which lowers blood sugar, slows the stomach and reduces appetite. Weight loss and blood sugar control come from the same effect; the label decides which one the product is approved to treat.
Different approved uses, and different people
| Ozempic | Wegovy | |
|---|---|---|
| First approval | December 2017 | June 2021 |
| Approved for | Blood sugar control in adults with type 2 diabetes | Weight management in adults and teens 12 and older with obesity, and adults with overweight plus a weight-related condition |
| Heart-risk reduction | Adults with type 2 diabetes and heart disease | Adults with heart disease and either obesity or overweight (March 2024) |
| Other uses | Slowing kidney decline in type 2 diabetes with chronic kidney disease (January 2025) | MASH liver disease with moderate to advanced fibrosis, accelerated approval (August 2025) |
| Children | Not approved | 12 and older (weight management) |
| Label starting dose | 0.25 mg once weekly | 0.25 mg once weekly |
| Label top dose | 2 mg once weekly | Usually 2.4 mg; up to 7.2 mg (Wegovy HD) |
| Devices | Multi-dose pens; single-dose syringes | Single-dose pens and syringes; FlexTouch pen (four 2.4 mg doses) |
| Tablet sibling | Ozempic tablets (type 2 diabetes) | Wegovy pill (weight and heart risk) |
| Self-pay (NovoCare) | $349 up to 1 mg; $499 at 2 mg | $349 up to 2.4 mg; $399 for 7.2 mg |
Ozempic label [1]; Wegovy label [2]; approval dates from Drugs@FDA [4] [5]; prices [10] [11].
The heart indications look alike but rest on different trials and different people. Ozempic's comes from SUSTAIN-6, in adults with type 2 diabetes at high heart risk, where semaglutide lowered heart attacks, strokes and heart deaths (hazard ratio 0.74) [8]. Wegovy's comes from SELECT, which enrolled 17,604 adults with heart disease and overweight but no diabetes; the risk fell by 20% (hazard ratio 0.80) [7]. Wegovy's label covers adults with heart disease and either obesity or overweight.
Ozempic's kidney indication comes from FLOW, where semaglutide 1 mg cut major kidney events by 24% in type 2 diabetes with chronic kidney disease [9]. Wegovy doesn't carry that indication; it carries MASH instead.
Wegovy's label goes higher, and the pens are different
Both labels start at 0.25 mg once a week. From there, Ozempic's label tops out at 2 mg a week [1]. Wegovy's usual maintenance dose is 2.4 mg a week, and since March 2026 its label allows up to 7.2 mg, sold as Wegovy HD [2]. Your prescriber sets the steps in between; they differ between the two labels.
The weight-loss evidence follows the higher doses. In STEP 1, people without diabetes on Wegovy's 2.4 mg dose lost 14.9% of their body weight on average over 68 weeks, against 2.4% on placebo [6]. That's a higher dose than Ozempic's label allows, so Ozempic's results in diabetes trials aren't a guide to Wegovy's.
The devices aren't swappable either. Ozempic comes mainly in multi-dose pens that deliver several weekly doses, plus single-dose syringes. Wegovy comes in single-dose pens and syringes, plus a FlexTouch pen holding four 2.4 mg doses [1] [2]. A box of Ozempic and a box of Wegovy at the "same" milligram dose are still different products.
The two pills are different too
Each brand now has a daily tablet, which adds to the confusion. Ozempic tablets, renamed from a newer Rybelsus formulation in January 2026, are approved for type 2 diabetes [3]. The Wegovy pill, approved in December 2025, is approved for weight management and heart-risk reduction [2]. Both contain semaglutide and share some tablet strengths, but they're separate products for separate uses. The Ozempic tablets label even says Rybelsus and Ozempic tablets "are not substitutable on a mg-to-mg basis" [3].
The semaglutide pill guide covers all the tablets, and Wegovy pill vs injection compares Wegovy's two forms.
Switching from Ozempic to Wegovy is a prescriber decision
People often ask to switch when their goal shifts toward weight, or when coverage changes. Because the two labels use different dose steps and ceilings, there's no simple swap at the same number, and your prescriber sets the starting point on the new product. Don't use both: Wegovy's label says combining it with other semaglutide products or any other GLP-1 drug "is not recommended" [2].
Side effects are the same kind, with more at higher doses
Ozempic's most common side effects are nausea, vomiting, diarrhea, abdominal pain and constipation [1]. Wegovy's list is longer, partly because of its higher doses, and adds headache, fatigue, indigestion, dizziness, bloating, burping, reflux, hair loss and dysesthesia, an unusual skin sensation [2]. Both carry the same boxed warning about thyroid C-cell tumors seen in rodents. The Wegovy side effects guide and Ozempic safety guide go symptom by symptom.
Cost and coverage: the same cash price, different insurance rules
| Product and dose | Ozempic | Wegovy |
|---|---|---|
| Pen, 0.25 mg and 0.5 mg, first 2 fills (new patients) | $199 | $199 |
| Pen, standard price | $349 (0.25 to 1 mg) | $349 (0.25 to 2.4 mg) |
| Pen, top dose | $499 (2 mg) | $399 (7.2 mg, Wegovy HD) |
| Pill | From $149 (1.5 mg) | $149 (1.5 mg), $199 (4 mg), $299 (9 and 25 mg) |
NovoCare [10] [11]. The intro offer runs through December 31, 2026, and NovoCare says pricing will be updated after that date. One month = one Ozempic pen or one box of four Wegovy pens.
In cash, the two cost the same at most doses. Insurance is where they split. A plan that covers diabetes drugs will usually cover Ozempic for type 2 diabetes, while many plans exclude weight-management drugs like Wegovy, unless a heart or liver indication applies. With commercial coverage, NovoCare's savings offer can bring either copay as low as $25 a month. The Ozempic cost guide and Wegovy cost guide cover both in depth.
What about compounded semaglutide?
Compounded semaglutide is a third thing, made by pharmacies rather than Novo Nordisk. Compounded drugs aren't FDA-approved, and FDA doesn't review them for safety, effectiveness or quality before they're sold. The compounded semaglutide vs Ozempic comparison explains what that means for you. For the weight-loss alternative from another maker, see Zepbound vs Wegovy, and for each brand on its own, the Ozempic guide and Wegovy guide.